Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.

EBioMedicine · 2023 · PMC10320523 · PMID 37354600

Europe PMC DOI

hedged sentence

0.1600

closest p · 3.2× alpha

0.1600

boldest claim

The sentences

showed a trendP = 0.16not close (p > 0.1)

comparator treatment in the low NfL group (HR = 0.52 [0.28–0.97]; P = 0.039 [log-rank]) and showed a trend for reduced CDP in the high NfL group (HR = 0.65 [0.34–1.21]; P = 0.16 [log-rank]), the latter being limited by sample size (27.4% of ocrelizumab arm, 38.2% of IFN arm at week 24).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.